A Phase 1/2a Study of Safety, Pharmacokinetics and Neutralizing Activity of SPK002 as pre-exposure prophylaxis of COVID-19 in healthy volunteers (Phase 1) and immunocompromised individuals (Phase 2a).

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505279-62-00

Acronym

EVEREST-2

Enrollment

Registered

2023-07-03

Start date

2023-07-10

Completion date

Unknown

Last updated

2023-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers (Phase 1), Immunocompromised individuals (phase 2a)

None listed

Sex/Gender

All

Age

18 Years to 64 Years

France

None listed

Source: EU CTIS · Data processed: Feb 4, 2026